Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Since the recent evidence-based medicine guidelines on bacterial
endocarditis management and prophylaxis (Durack DT et al 1998), successive updates and expert panels have described new aspects in
primary and secondary prophylaxis. The state-of-the-art paper of Durack DT (Prevention of infective endocarditis. NEJM 1995; 332: 38-44) is a well-stablished description. Bayer AS et al described the diagnosis and
management of infective endocarditis and its complications integrated in prevention (Circulation 1998).
The state-of-the-art paper of the Task Force on Infective Endocarditis of the
ESC (guidelines on prevention, diagnosis and treatment. Eur Heart J 2004; 25: 267-76) would be another example of consensus.
Competing interests:
No competing interests
24 June 2011
Sabino G Echebarria Mendieta
MD neurologist
H San Eloy( Barakaldo-Bizkaia )district clinics.Osakidetza-Basque Health Service
Endocarditis prophylaxis
Since the recent evidence-based medicine guidelines on bacterial
endocarditis management and prophylaxis (Durack DT et al 1998), successive updates and expert panels have described new aspects in
primary and secondary prophylaxis. The state-of-the-art paper of Durack DT (Prevention of infective endocarditis. NEJM 1995; 332: 38-44) is a well-stablished description. Bayer AS et al described the diagnosis and
management of infective endocarditis and its complications integrated in prevention (Circulation 1998).
The state-of-the-art paper of the Task Force on Infective Endocarditis of the
ESC (guidelines on prevention, diagnosis and treatment. Eur Heart J 2004; 25: 267-76) would be another example of consensus.
Competing interests: No competing interests